CORRECTING and REPLACING AVANIR Pharmaceuticals Invites Investors to Its First Quarter Conference Call on Thursday, February 9,
18 Gennaio 2006 - 5:25PM
Business Wire
First graph, first sentence of release should read: Thursday,
February 9, 2006 (sted Wednesday, February 9, 2006). The corrected
release reads: AVANIR PHARMACEUTICALS INVITES INVESTORS TO ITS
FIRST QUARTER CONFERENCE CALL ON THURSDAY, FEBRUARY 9, 2006 AVANIR
Pharmaceuticals (AMEX: AVN.R) will webcast its quarterly conference
call on Thursday, February 9, 2006 at 1:30 p.m. Pacific/ 4:30 p.m.
Eastern. The call will be webcast live through AVANIR's corporate
website at www.avanir.com and will feature Eric Brandt, President
and Chief Executive Officer, and Gregory P. Hanson, Vice President
and Chief Financial Officer. A press release announcing the first
quarter 2006 financial results will be released prior to the
conference call the same day. It is recommended that you go to
AVANIR's website at least 10 minutes in advance of the webcast to
download any applicable software. For those who cannot listen to
the live broadcast, the online replay will be available for 90
days, and a phone replay will be available through February 13,
2006, by dialing 800-642-1687 (domestic) and 706-645-9291
(international) and entering the passcode 4490357. AVANIR
Pharmaceuticals is focused on developing and commercializing novel
therapeutic products for the treatment of chronic diseases.
AVANIR's product candidates address therapeutic markets that
include central nervous system and cardiovascular disorders,
inflammation, and infectious diseases. AVANIR previously announced
positive results in the second of two required Phase III clinical
trials of Neurodex(TM), an investigational new drug for the
treatment of pseudobulbar affect. Additionally, AVANIR has
initiated a Phase III clinical trial for Neurodex as a potential
treatment in patients with diabetic neuropathic pain, a second
indication for Neurodex. AVANIR has active collaborations with two
international pharmaceutical companies: Novartis International
Pharmaceutical Ltd. for the treatment of inflammatory disease and
AstraZeneca for the treatment of cardiovascular disease. The
Company's first commercialized product, Abreva(R), is marketed in
North America by GlaxoSmithKline Consumer Healthcare and is the
leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.
The information contained in this press release, including any
forward-looking statements contained herein, should be reviewed in
conjunction with the company's most recent Annual Report on Form
10-K and quarterly report on Form 10-Q and other publicly available
information regarding the Company. Copies of such information are
available from the company upon request. Such publicly available
information sets forth many risks and uncertainties related to the
company's business and technology. Forward-looking statements often
contain such words like "estimate," "anticipate," "believe," "plan"
or "expect". Avanir disclaims any intent or obligation to update
these forward-looking statements.
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Avanir Pharmaceuticl (Borsa Americana (AMEX)): 0 articoli recenti
Più AVANIR Pharmaceuticals Articoli Notizie